The Life Sciences Report
For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.
The Approval Process in Action
Source: The Life Sciences Report and Visual Capitalist (5/1/13)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
Notable Quotes
Threshold Pharmaceuticals Inc. "THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) - The Life Sciences Report Interview with George Zavoico More >
Can-Fite BioPharma Ltd. "CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) - The Life Sciences Report Interview with Reni Benjamin More >
Sunesis Pharmaceuticals Inc. "There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) - The Life Sciences Report Interview with Mara Goldstein More >
Neuralstem Inc. "If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) - The Life Sciences Report Interview with Edward Stopke More >
Athersys Inc. "ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) - The Life Sciences Report Interview with Edward Stopke More >